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           TNF receptor superfamily 25 (TNFRSF25 
[TNFR25]) was cloned by several groups un-
der the names Wsl-1, Apo3, LARD, TRAMP, 
DR3, and TR3 (  1  –  6  ) as a member of the TNF-
receptor family with a typical death domain. 
Transfected TNFR25 has been shown to in-
duce rapid apoptosis by activating the caspase 
cascade through interaction with TRADD and 
FADD (  4, 7, 8  ). Like other TNF receptor fam-
ily members, TNFR25 is also able via TRADD 
and TRAF2 to induce NF-    B and promote 
cell survival signals (  2, 5, 9  –  12  ). TNFR25 is ex-
pressed constitutively in the form of randomly 
spliced transcripts, primarily in lymphoid cells 
(  2, 3, 13  ) but also in other cells, including tu-
mor cells (  6, 14  ). 
  The ligand for TNFR25 has recently been 
identifi  ed as TL1A (TNFSF15) (  11  ). TL1A 
has co-stimulatory activity for TNFR25-ex-
pressing T cells through the activation of 
NF-    B and suppression of apoptosis by up-
regulation of c-IAP2 (  12  ). TL1A expression 
is detected on human umbilical vein endo-
thelial cells and mediates antiangiogenic ac-
tivity (  15  ). Up-regulated expression of TL1A 
is also found on macrophages and lympho-
cytes in human infl  ammatory bowel disease 
and correlated with the severity of infl  amma-
tion, implying that TL1A/TNFR25 signals 
may be involved in infl  ammatory bowel dis-
ease (  16, 17  ). TL1A synergizes with IL-12 
and -18 to promote IFN-     production in 
human T cells and NK cells (  18  ). Whether 
TL1A/TNFR25 signals play a role in Th2-
mediated functions and disease pathology has 
not been investigated. 
  Germ line deletion of TNFR25 in mice dis-
played a partial defect in negative selection of 
thymocytes; however, no phenotypic changes 
were observed in TNFR25-defi  cient peripheral 
T cells compared with WT cells (  19  ). 
  Allergic, atopic lung infl  ammation is thought 
to be one of the underlying causes for air-
way hyperreactivity and asthma. It is char-
acterized by IL-13 production by NKT and 
T cells; by Th2 polarization of CD4 cells 
associated with elevated IgE levels; by cel-
lular, prominently eosinophilic, infi  ltration 
into the peribronchial space and broncho-
alveolar fl  uid; and by goblet cell hyperpla-
sia and increased mucus production (  20  –  24  ). 
In this study, we show that TNFR25 is a 
molecular trigger for amplifi   ed Th2 cyto-
kine production by polarized CD4 cells and 
for IL-13 production by NKT cells, and that 
blockade of TNFR25 inhibits allergic lung 
infl  ammation, a cardinal feature of asthma, in 
murine models. 
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  We identify the tumor necrosis factor receptor superfamily 25 (TNFRSF25)/TNFSF15 pair 
as critical trigger for allergic lung infl  ammation, which is a cardinal feature of asthma. 
TNFRSF25 (TNFR25) signals are required to exert T helper cell 2 (Th2) effector function in 
Th2-polarized CD4 cells and co-stimulate interleukin (IL)-13 production by glycosphingo-
lipid-activated NKT cells. In vivo, antibody blockade of TNFSF15 (TL1A), which is the ligand 
for TNFR25, inhibits lung infl  ammation and production of Th2 cytokines such as IL-13, 
even when administered days after airway antigen exposure. Similarly, blockade of TNFR25 
by a dominant-negative (DN) transgene, DN TNFR25, confers resistance to lung infl  amma-
tion in mice. Allergic lung infl  ammation  –  resistant, NKT-defi  cient mice become susceptible 
upon adoptive transfer of wild-type NKT cells, but not after transfer of DN TNFR25 trans-
genic NKT cells. The TNFR25/TL1A pair appears to provide an early signal for Th2 cytokine 
production in the lung, and therefore may be a drug target in attempts to attenuate lung 
infl  ammation in asthmatics. 1038 TNFRSF25 IN ASTHMA | Fang et al.
CD8 cells expressed TNFR25 at levels similar to naive pe-
ripheral T cells. CD4/CD8 double-positive and -negative 
thymocytes did not express TNFR25 (unpublished data). 
The high level of constitutive TNFR25 expression on NKT 
cells suggested that TNFR25 may have important functions 
in NKT co-stimulation. 
  NKT cells are early mediators of immune responses by 
rapidly secreting IFN-     or IL-13/IL-4. NKT cells have 
been implicated in Th1/Th2 polarization and in the patho-
genesis of lung infl  ammation (  25  ), autoimmunity, and anti-
tumor immunity (  26  –  29  ). Using an agonistic anti-TNFR25 
antibody (4C12), we determined whether signals emanating 
from TNFR25 on NKT cells had eff  ects on their secretion 
of Th1 or Th2 cytokines. NK/NKT cells were enriched 
from pooled spleen cells of 10 mice by positive selection 
    RESULTS   
  TNFR25 is constitutively expressed on NKT cells 
and co-stimulates IL-13 production 
  To study the biological functions of TNFR25 and its cognate 
ligand TL1A, hamster anti  –  mouse monoclonal antibodies to 
TNFR25 were generated by standard protocols and used to 
measure TNFR25 expression by fl  ow cytometry on primary 
lymph node and spleen cells. TNFR25 was detected at 
low levels on naive CD4 T cells, and at even lower levels on 
CD8 T cells. In contrast, NKT cells expressed high levels of 
TNFR25 (  Fig. 1 A  ).   A subpopulation of CD11c  +   cells and 
NK cells were also TNFR25 positive, whereas B cells were 
negative. We confi  rmed previous data that activated CD4 
and CD8 T cells up-regulated TNFR25 expression (unpub-
lished data) (  13  ). In the thymus, single-positive CD4 and 
    Figure 1.     TNFR25 is constitutively expressed on resting NKT cells and co-stimulates IL-4 and -13 cytokine production.   (A) Expression of 
TNFR25 in lymph node cells. Cells were gated for CD4, CD8, B220, CD11c, or NK1.1-positive and CD3-negative cells or NK1.1/CD3 double-positive cells 
and TNFR25 fl  uorescence displayed in the histogram. Red curve, anti-TNFR25; black curve, isotype control. (B) TNFR25 co-stimulation of IL-4 and -13 
production by glycosphingolipid-activated NKT cells. NKT cells were enriched from pooled spleen cells from 10 mice by positive selection using the Easy-
Sep mouse Pan NK Positive Selection kit. The ratio of NK to NKT cells in the enriched population was 65:35   ×   10  5   cells were incubated for 48 h in fl  at bot-
tom 96-microtiter plates in triplicate in the presence of 10 ng/ml IL-15 and stimulated with 20, 100, or 500 ng/ml OCH-glycosphingolipid. Co-stimulation 
was achieved with 5   μ  g/ml agonistic anti-TNFR25 antibody 4C12 as indicated; cytokines were analyzed in supernatants by ELISA. n.d., not detectable. 
Representative of three independent experiments. (C) TNFR25 co-stimulation increases the frequency of IL-13  –  producing NKT cells. Enriched NK/NKT cells 
purifi  ed as described above were incubated with increasing concentrations of plate-bound anti-CD3, as indicated in the presence and absence of 5   μ  g/ml 
agonistic anti-TNFR25 (4C12) for 72 h. Details of the method for intracellular cytokine staining are given in Materials and methods. In negative controls 
for unspecifi  c staining, anti  –  IL-13 was blocked with recombinant IL-13 before use in intracellular staining (see Materials and methods) and were given 
values of   <  1%. Data for intracellular staining of IL-13 and IFN-     in NKT cells were obtained by gating on NK1.1 and CD3 double-positive cells. Data are 
taken from two experiments. Error bars represent the mean   ±   the SEM.     JEM VOL. 205, May 12, 2008 
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fore are able to present lipids to the TCR of invariant NKT 
cells. NKT cells were stimulated with increasing concentra-
tions of the glycosphingolipid OCH or with anti-CD3, 
using a mouse pan-NK-Positive Selection kit (StemCell 
Technologies), resulting in a population composed of 65% 
NK and 35% NKT cells. NK cells express CD1d and there-
    Figure 2.     TL1A-triggered TNFR25 signals are blocked by antagonistic anti-TL1A L4G6.   (A) TL1A is not expressed on resting lymphocytes and up-
regulated on activated T cells (top 6 graphs). Resting splenocyte cell suspensions were gated using the respective labeled antibody as a population marker 
and the TL1A histogram displayed. Red curve, anti-TL1A; black curve, isotype control (bottom 3 graphs). Splenocytes were activated for 24 h with plate-
bound anti-CD3 or with LPS and stained with anti-TL1A and with the population marker, as indicated. After gating on the population marker, TL1A ex-
pression on activated cells is shown as blue/shaded histogram. Red curve, resting cells; black curve, isotype control. Representative of more than three 
experiments. (B) TNFR25 and TL1A expression on cDNA transfected P815 and EL4. Transfected (right curve in each histogram) and untransfected cells 
were stained with the appropriate antibody and isotype controls and analyzed by fl  ow cytometry. (C) TNFR25 activates NF-    B when triggered by agonistic 
antibody 4C12, by soluble TL1A or by membrane-bound TL1A. NF-    B activation was measured in EL4 cells transfected with TNFR25 in response to TNFR25 
triggering. Cells were treated with the agonistic anti-TNFR25 antibody 4C12 (5   μ  g/ml) for 50 min; soluble TL1A was given for 25, 50, or 70 min, as indi-
cated in the form of 25% supernatants from TL1A-transfected EL4 cells; membrane-bound TL1A (MTL1A) was given for 50 min by adding TL1A-transfected 
EL4-cells directly to TNFR25-transfected EL4. Controls received EL4 (untransfected) supernatants for 50 min. Nuclear extracts were prepared and analyzed 
by EMSA; the arrow indicates activated NF-    B. (D) Anti-TL1A antibody L4G6 blocks TL1A induced cell death of TNFR25-transfected cells. Soluble TL1A 
harvested from supernatants of P815-TL1A  –  transfected cells were mixed with   51  Cr-labeled P815-TNFR25 target cells. Different anti-murine TL1A mono-
clonal antibodies were added into the assay, and   51  Cr release was analyzed 5 h later. L4G6 antibody completely blocked the ability of TL1A to induce apop-
tosis in TNFR25-transfected P815 cells.     1040 TNFRSF25 IN ASTHMA | Fang et al.
with and without co-stimulation of TNFR25 by the ago-
nistic anti-TNFR25 antibody 4C12. OCH is a derivative of 
    -galactosylceramide with a shortened sphingosine chain. 
After 2 d of stimulation with increasing concentrations of 
OCH in the presence or absence of agonistic anti-TNFR25 
(4C12), the supernatants were harvested and analyzed for 
IL-13, IL-4, and IFN-     by ELISA (  Fig. 1 B  ). TNFR25 sig-
nals co-stimulated lipid-dependent IL-13 production and, 
to a lesser extent, IL-4 production, but had no eff  ect on 
IFN-     production. In the absence of lipid, anti-TNFR25 
alone did not induce production of any of the cytokines 
(unpublished data). TNFR25 signals also up-regulated the 
frequency of IL-13  –  secreting NKT cells, as detected by in-
tracellular staining and gating on NK1.1/CD3 double-positive 
cells (  Fig. 1 C  ). TNFR25-mediated IL-13 co-stimulation 
was most pronounced at an anti-CD3 concentration of 0.3  –
  1   μ  g/ml, suggesting sensitivity of TNFR25 co-stimulation 
to antigen concentration. IFN-     responses occur at lower 
anti-CD3 concentrations, but are not subject to TNFR25 
co-stimulation. 
  TL1A is expressed on activated CD4 and CD8 T cells 
and activates NF-    B and apoptosis in TNFR25-transfected cells 
  To study the ligand for TNFR25, we generated monoclonal 
antibodies to murine TL1A for fl  ow cytometry and func-
tional studies. Resting lymph node cells are TL1A negative, 
including NKT and T cells, B cells, NK cells, and DCs (  Fig. 
2 A  ).   After activation with anti-CD3 or LPS, respectively, 
CD4 and CD8 T cells express TL1A, whereas activated B 
cells remain TL1A negative. TL1A expression on activated 
T cells is transient and disappears after     48 h. All tissues ana-
lyzed, including lung, are TL1A negative when analyzed by 
PCR or fl  ow cytometry. We set out to identify TL1A-block-
ing antibodies to generate tools to elucidate the in vivo func-
tion of TL1A  –  TNFR25 interaction. 
  TL1A-transfected tumor cells permanently express 
TL1A, which is detectable both as membrane-bound pro-
tein by fl  ow cytometry (  Fig. 2 B  ) and in cell-free superna-
tant as soluble TL1A by ELISA (not depicted) and by 
functional activity. Both soluble and membrane-bound 
TL1A are able to trigger TNFR25 signals (  Fig. 2, C and 
D  ). Similar to TNF, membrane-bound and soluble TL1A 
activate NF-   B ( Fig. 2 C ) and induce apoptosis in TNFR25-
transfected tumor cells (  Fig. 2 D  ), as has been previously 
reported (  1  –  6, 10  ). The anti-TNFR25 agonistic antibody 
4C12 used in   Fig. 1 B   also activated NF-    B (  Fig. 2 C  ) and 
mediated apoptosis of TNFR25-transfected tumor cells 
(not depicted). 
  We determined whether any of the anti-TL1A antibodies 
we had generated exhibited blocking activity for TL1A-
mediated apoptosis of TNFR25-expressing targets. One of 
the anti-TL1A antibodies, L4G6, completely blocked TL1A-
mediated lysis of TNFR25-transfected cells, whereas several 
other anti-TL1A antibodies had no eff  ect (  Fig. 2 D  ). There-
fore, L4G6 antibody was selected for in vivo blockade of 
TL1A in genetically unmodifi  ed WT mice. 
    Figure 3.     Antagonistic anti-TL1A antibody (L4G6) blocks lung 
infl  ammation.   (A) Diminished cellular exudation in BALF in anti-TL1A 
(L4G6)  –  treated mice. Mice were primed i.p. on day 0 and 5 with 66   μ  g 
ovalbumin absorbed to alum. On day 12, mice were aerosol challenged 
with 0.5% ovalbumin in PBS for 1 h using an ultrasonic nebulizer. Mice 
received 4 daily doses of 50   μ  g purifi  ed L4G6-IgG i.p. (anti-TL1A), begin-
ning 1 d before aerosol. Controls received the same amount and schedule 
of purifi  ed hamster IgG. All mice were analyzed 3 d after aerosol antigen 
exposure (  n   = 4; representative of   >  10 experiments). *, P   <   0.05; **, P   <   
0.01. (B) TL1A-blocking antibody L4G6 suppresses mucus production and 
lung infl  ammation. Lung histology after PAS staining after treatment of 
mice with control IgG (top) or L4G6-IgG (anti-TL1A; bottom). Notice the 
lack of mucus production and cell infi  ltration in L4G6-treated animals 
(arrows point to mucus in mice treated with control IgG). Experiments 
were repeated three times. (C) Diminished IL-5 and -13 production by 
ovalbumin restimulated bronchial lymph node cells after TL1A blockade 
with L4G6. Bronchial lymph node cells were harvested 3 d after aerosol 
and restimulated in vitro with 100   μ  g/ml ovalbumin for 4 d. IL-4 was not 
detectable (not depicted), even in the absence of anti-TL1A.   n   = 4; **, 
P   <   0.01; ***, P   <   0.001. Experiments were repeated more than three times. 
(D) Cytokine expression in lung parenchyma after ovalbumin aerosol 
exposure. Lungs were harvested 1, 2, or 3 d after ovalbumin aerosol 
treatment. RNA was extracted, and after reverse transcription it was ana-
lyzed by Taqman PCR. Values are normalized to GAPDH cDNA and ex-
pressed as the fold increase of ovalbumin aerosol  –  treated over untreated 
mice. (E) Blocking anti-TL1A antibody L4G6 suppresses ovalbumin-
induced cytokine expression in lung parenchyma. Mice were immunized 
twice with ovalbumin/alum, as described. 1 d before ovalbumin aerosol 
and for the next 3 d, mice received 50   μ  g blocking TL1A antibody L4G6 or 
control IgG i.p. Lungs were analyzed for expression of cytokine mRNA on 
day 1  –  3 after aerosol administration by Taqman PCR, as above. Data are 
presented as anti-TL1A  –  induced suppression of cytokine mRNA over 
control  IgG.   JEM VOL. 205, May 12, 2008 
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  To test TNFR25 blockade with anti-TL1A, mice were 
immunized twice with ovalbumin in alum on day 0 and 5, 
and were airway challenged on day 12 with aerosolized oval-
bumin. 1 d before airway challenge, and for the next 3 d, 50 
  μ  g anti-TL1A-IgG L4G6 or control hamster IgG was admin-
istered i.p., and the mice were analyzed the next day. L4G6 
administered in this way at the time of aerosol challenge 
strongly inhibited lung infl   ammation, as indicated by de-
creased cellular exudation into BALF (  Fig. 3 A  ) and by re-
duced mucus production as detected in tissue section by 
periodic acid-Schiff   (PAS) staining (  Fig. 3 B  ).   In anti-TL1A 
(L4G6)  –  treated mice, IL-13 and -5 secretion by bronchial 
draining lymph node cells upon restimulation with oval-
bumin in vitro was signifi  cantly inhibited compared with 
  Antibody blockade of TL1A inhibits lung infl  ammation 
of antigen-primed mice even after airway antigen reexposure 
  The eff  ect of TNFR25 signals on IL-13 secretion by NKT cells 
(  Fig. 1 B  ) suggested that TNFR25 may be an important co-
stimulus for IL-13 production in the lung. Invariant NKT cells 
producing IL-13 have previously been shown to be essential for 
the induction of lung infl  ammation and airway hyperreactivity 
in the murine ovalbumin model for allergic, atopic lung infl  am-
mation (  23  ). We therefore tested whether blockade of TNFR25 
signals in vivo would have eff  ects on lung infl  ammation in the 
classical ovalbumin model. Blockade of TNFR25 signals in vivo 
can be achieved by blocking the cognate ligand TL1A with an 
antagonistic TL1A antibody (L4G6) or by genetic means, gen-
erating dominant-negative (DN) mutants of TNFR25. 
    Figure 4.     Kinetics of inhibition of lung infl  ammation by administration of blocking and nonblocking anti-TL1A.   Mice were immunized and 
subjected to ovalbumin aerosol according to our standard protocol. Administration of 50   μ  g blocking (L4G6) or nonblocking (L3A10) anti-Tl1A, or control 
hamster IgG i.p. was started at the time indicated relative to aerosol exposure and continued daily until analysis, which was at 76 h after aerosol. In the 
72-h time points, anti-TL1A was administered 4 h before analysis. A, B, and C are separate experiments testing different schedules and controls. Note that 
nonblocking TL1A (L3A10) does not affect eosinophil exudation, similar to hamster IgG. (A and B) Data from three experiments with two mice. (C) Data 
from two experiments with fi  ve mice. (D and E) Histopathology of lung sections stained with HE and PAS. Five sections from each of three mice in each 
group were evaluated in a blinded fashion according to the scoring system described in Materials and methods. (F and G) Relative frequency of CD4 and 
CD8 cells in lung parenchyma after aerosol exposure and blockade of TL1A for different periods of time. Single-cell suspensions were analyzed by fl  ow 
cytometry gating on the lymphocyte gate. (H  –  J) RNA was isolated from whole lungs and analyzed by real-time PCR as in   Fig. 3  . Error bars represent the 
mean   ±   the  SEM.   1042 TNFRSF25 IN ASTHMA | Fang et al.
before to 72 h after ovalbumin aerosol exposure (  Fig. 4  ).   
Anti-TL1A fully blocked lung infl  ammation when adminis-
tration started at     24, 0, and +24 h relative to airway antigen 
exposure. Signifi   cant inhibition of lung infl  ammation  by 
anti-TL1A was still observed, even when the antibody was 
administered 48 and 72 h after aerosol exposure. The 72-h 
time point allowed for only 4 h of in vivo action of anti-
TL1A, but was still able to signifi  cantly reduce eosinophil in-
fi  ltration by     50%, suggesting potential therapeutic activity 
(  Fig. 4 C  ). The rapid reduction of eosinophils in BALF 
within 4 h after anti-TL1A administration suggests that anti-
TL1A disrupts an ongoing infl  ammatory reaction recruiting 
eosinophils and/or supporting their maintenance. Histopa-
thology by hematoxylin and eosin (HE) and PAS staining of 
IgG-treated control mice (  Fig. 3 C  ). IL-4 was undetectable in 
control and anti-TL1A  –  treated mice. 
  Lung infl  ammation in the ovalbumin model is known to 
be associated with Th2 cytokine production in bronchial 
lymph nodes. Using Taqman PCR assays, we found IL-13 
mRNA to be up-regulated by   >  100-fold and IL-5 mRNA 
to a lower degree in lung tissues of ovalbumin-aerosolized 
mice (  Fig. 3 D  ). Anti-TL1A administration started 1 d before 
aerosol blocked the up-regulation of Th2 cytokine mRNA 
(  Fig. 3 E  ). 
  To determine whether TL1A blockade of lung infl  am-
mation was eff  ective even when started after airway antigen 
reexposure, we compared the eff  ect of TL1A blockade on 
infl  ammation by beginning antibody administration from 24 h 
    Figure 5.         DN TNFR25 transgene blocks TNFR25 signaling and interferes with Th2 cytokine production upon secondary stimulation.   (A)  Ex-
pression of DN-TNFR25-tg on lymph node cells. Lymph node cells were gated on CD4, CD8, CD11c, B220, DX5, or NK1.1/CD3; TNFR25 expression is dis-
played in the histogram. Black curves, isotype controls; red curves, DN TNFR25-tg lymph node cells; green curves, nontransgenic lymph node cells from 
littermates; all cells are in resting, nonactivated state. (B) DN TNFR25-tg blocks cytokine co-stimulation by agonistic anti-TNFR25 (4C12). Purifi  ed WT and 
DN TNFR25-tg (DN) CD4 cells were stimulated for 3 d with anti-CD3 with or without the agonistic anti-TNFR25 antibody 4C12 (5   μ  g/ml). The superna-
tants were analyzed for cytokines by ELISA. (C) DN TNFR25-tg CD4 T cells do not exert Th2 cytokine production in secondary activation. WT and DN 
TNFR25-tg CD4 T cells were purifi  ed by negative selection and activated with 2   μ  g/ml immobilized anti-CD3 and 1   μ  g/ml soluble anti-CD28 for 3 d under 
Th cell neutral conditions (no cytokines were added). Cells were harvested, washed, replated, and restimulated with 1   μ  g/ml immobilized anti-CD3 for 2 d. 
The supernatants were collected for cytokine ELISA assay. All experiments were performed more than three times with reproducible results. Error bars 
represent the mean   ±   the SEM. ***, P   <   0.001.     JEM VOL. 205, May 12, 2008 
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elicited with the agonistic anti-TNFR25 antibody 4C12. This 
co-stimulation by 4C12 is not observed in DN TNFR25-tg 
CD4 cells (  Fig. 5 B  ), indicating that the DN TNFR25 trans-
gene product blocks the function of endogenous TNFR25. 
Similarly, TNFR25 signals co-stimulated proliferation of 
activated WT CD4 cells, and this co-stimulation is not 
observed in DN TNFR25-tg CD4 cells (unpublished data) 
the lung revealed decreased numbers of infi  ltrating  cells 
around blood vessels and bronchioli and decreasing mucus 
already within 4 h of TL1A blockade (  Fig. 4, D and E  ). The 
relative frequency of CD4 and CD8 cells detected in the 
lymphoid gate in the lung parenchyma is slightly increased 
after 4 h TL1A blockade and decreases upon longer L4G6 
presence (  Fig. 4, F and G  ). The early, relative increase in the 
frequency of CD4 and CD8 cells after only 4 h of TL1A 
blockade may be caused by the rapid loss of eosinophils that 
represent a large proportion of infi   ltrating cells. The fre-
quency of NKT cells varied in the lymphoid gate in all sam-
ples without a clear tendency of change (unpublished data). 
Anti-TL1A, present for 4 and 24 h, suppressed IL-4, -5, and -13 
mRNA but did not aff  ect IFN-     mRNA (  Fig. 4, H and J  ). 
The data suggest that TL1A blockade has immediate inhibi-
tory eff  ects on the eff  ector phase of lung infl  ammation with-
out early eff  ects on lymphoid cell populations. 
  Our data support the concept that TL1A is needed for 
the engagement of TNFR25 in vivo, and that continuous 
TNFR25 signals contribute to or are critical for Th2 and IL-
13 production and lung infl  ammation. To further test and 
independently confi  rm that blockade of TNFR25 signals in-
hibit susceptibility to allergic lung infl  ammation, we devel-
oped a genetic model for TNFR25 blockade on T cells and 
NKT cells by creating a DN TNFR25 transgene that is ex-
pressed on T cells. 
  DN TNFR25 transgene blocks TNFR25 signaling 
and lung infl  ammation 
  To confi  rm the role of TNFR25 in the induction of lung in-
fl  ammation by independent, genetic methods, we generated 
a DN mutant of TNFR25, DN TNFR25, and expressed the 
construct as transgene under the CD2 promoter and enhancer 
on T cells and NKT cells. The DN TNFR25-transgene is 
lacking the entire intracellular signaling domain, but is identi-
cal to full-length TNFR25 in its transmembrane and extra-
cellular domain. Trimerization of DN TNFR25 with 
endogenous TNFR25 is expected to extinguish TNFR25 
signaling. Transgenic DN TNFR25 was expressed constitu-
tively on resting T cells, NKT, NK, and a subpopulation of 
CD11c  +   cells (  Fig. 5 A  , red) as determined by fl  ow cytome-
try. The expression of endogenous TNFR25 on resting cells 
of nontransgenic litter mates is also shown (in green in   Fig. 5 A  ).   
The fl  uorescence intensity indicates that the DN TNFR25 
expression level is higher than endogenous TNFR25 and 
may be suffi   cient to act as a DN mutant. DN TNFR25-
transgene (tg) mice appear healthy, and they have normal 
white cell counts in thymus, spleen, and lymph nodes. The 
number and phenotype of CD4  +   and CD8  +   T cells, B cells, 
CD11c  +   cells, NK, and NKT cells is normal. 
  To assure that the level of overexpression of DN TNFR25 
silenced the activity of endogenous TNFR25, several experi-
ments were performed. Primary anti-CD3 activation of naive 
WT and DN-TNFR25-tg CD4 cells stimulates Th1 and 
Th2 cytokine secretion equally (  Fig. 5 B  ). In WT CD4 cells, 
cytokine production is co-stimulated by TNFR25 signals 
    Figure 6.     Genetic blockade of TNFR25 abolishes lung infl  amma-
tion.   (A) Diminished cellular exudation in BALF in DN TNFR25-tg mice. 
Mice were primed and aerosol challenged with ovalbumin according to 
our standard protocol.   n   = 5. *, P   <   0.05. (B and C) Suppression of lung 
infl  ammation in DN TNFR25-tg mice after immunization and airway chal-
lenge. Lung infl  ammation was induced by ovalbumin immunization, and 
subsequent aerosol exposure as described. (B) Wild-type B6. (C) DN 
TNFR25-tg B6 mice. Note absence of perivascular infi  ltrates in DN 
TNFR25-tg mice after antigen aerosol exposure and absence of mucus 
over production and goblet cell hyperplasia in DN TNFR25-tg mice. 
(D) Suppression of Th2, but not Th1, cytokine production in DN TNFR25-tg 
bronchial lymph nodes from aerosol-challenged mice. Bronchial lymph 
nodes were harvested 3 d after aerosol challenge, and lymph node cells 
were prepared and restimulated with 100   μ  g/ml ovalbumin for 4 d. Super-
natants were then analyzed for cytokine production by ELISA. This fi  gure 
is the representative of two independent experiments (  n   = 4). n.d., not 
detected. *, P   <   0.05. Error bars represent the mean   ±   the SEM.     1044 TNFRSF25 IN ASTHMA | Fang et al.
cells and amplifying Th2 cytokine production by Th2-polar-
ized CD4 cells. To directly test the role of NKT cells in vivo, 
adoptive transfer experiments with DN-TNFR25-tg NKT 
cells were performed. 
  Adoptive transfer of DN TNFR25-tg NKT cells does not 
restore lung infl  ammation in NKT-defi  cient mice. 
  To further assess the role of TNFR25 in NKT cell function 
in lung infl  ammation, we made use of the fact that NKT-de-
fi  cient mice (J    18 KO) (  27  ) are resistant to induction of lung 
infl  ammation in the ovalbumin model (  21, 23, 24  ). Adoptive 
transfer of WT NKT cells to NKT-defi  cient, J    18 KO mice 
restores lung infl  ammation and airway hyperreactivity in the 
ovalbumin model. Akbari et al. (  23  ) also showed that adop-
tive transfer of NKT cells from IL-13-defi  cient mice did not 
restore lung infl  ammation in J    18 KO mice, demonstrating 
the importance of IL-13 production by NKT cells in the in-
duction of lung infl  ammation. Because our data indicated 
that IL-13 production by NKT cells is co-stimulated by 
TNFR25, we hypothesized that adoptive transfer of DN 
TNFR25-tg NKT cells likewise would not be able restore 
lung infl  ammation in NKT-defi  cient mice. 
  We purifi  ed NK/NKT cells by positive selection from the 
spleens of 10 mice, and we adoptively transferred i.v. 1 million 
DN TNFR25-tg NKT cells, corresponding to 3 million NK/
NKT cells, into ovalbumin-primed, NKT-defi  cient (J    18 KO) 
mice (  27  ). Adoptive transfer of 1 million WT NKT cells served 
as controls. On the day after adoptive transfer the mice were 
subjected to aerosolized ovalbumin. 3 d later, lung infl  amma-
tion was measured by the degree of eosinophil exudation into 
the BALF (  Fig. 7 A  ) and by cytokine mRNA expression in 
lung parenchyma and bronchial draining lymph nodes (  Fig. 7, 
B and C  ).   Although adoptively transferred WT NKT cells 
restored lung infl  ammation and BALF eosinophilia upon air-
way antigen challenge, the same number of DN TNFR25-tg 
NKT cells was unable to do so (  Fig. 7  ). The diminished BALF 
eosinophilia (  Fig. 7 A  ) observed in DN TNFR25-tg NKT 
cell-transferred mice was associated with diminished Th2 cyto-
kine mRNA induction in lung tissues and in bronchial drain-
ing lymph nodes (  Fig. 7, B and C  ). In lung tissue, IL-13 
mRNA was markedly reduced, whereas in bronchial lymph 
nodes, IL-4 and -5 mRNA were also strongly aff  ected by the 
absence of functional TNFR25 on NKT cells. In addition, 
TL1A mRNA was twofold higher in mice receiving WT 
NKT cells, suggesting positive feedback amplifi  cation of TL1A 
expression by TNFR25-induced Th2 cytokine production. 
The data demonstrate that TNFR25 signals in NKT cells are 
necessary and suffi   cient for triggering lung infl  ammation dur-
ing airway antigen exposure of sensitized mice even under 
conditions when normal TNFR25-signals can be elicited 
on CD4 cells. 
    DISCUSSION   
  The signature cytokine of asthma is IL-13 (  30  ), and NKT 
cells appear to be an important early source of IL-13 produc-
tion in the lung (  23  ). Our study indicates that an essential 
indicating that endogenous TNFR25 is silenced by the DN 
mutant TNFR25. 
  It is well established that cytokine production by CD4 cells 
is greatly amplifi  ed upon secondary stimulation. Importantly, 
DN TNFR25-tg CD4 cells upon secondary activation do not 
support up-regulated production of Th2 cytokines, while al-
lowing amplifi  ed IFN-     production (  Fig. 5 C  ), suggesting that 
TNFR25 signals are required for amplifi  ed Th2 cytokine secre-
tion. The data suggest that TNFR25 may have a dual eff  ect in 
lung infl  ammation by co-stimulating IL-13 secretion by NKT 
cells and by amplifying Th2 cytokine production in ovalbu-
min-restimulated CD4 T cells in the lung. Based on these ob-
servations, we tested whether DN-TNFR25-tg mice showed 
an altered response to the induction of lung infl  ammation in 
our ovalbumin model. 
  Ovalbumin-primed, DN TNFR25-tg mice upon airway 
challenge with ovalbumin exhibited signifi  cantly diminished 
eosinophilic infi  ltration in BALF (  Fig. 6 A  ), absent lung in-
fl  ammation and mucus production by histopathology (  Fig. 6, B 
and C  ), and diminished ovalbumin-specifi  c IgE production 
(unpublished data) in serum.   In vitro, ovalbumin restimulation 
of bronchial draining lymph node cells harvested from primed 
and airway-challenged DN TNFR25-tg mice mediated di-
minished Th2 cytokine production but normal IFN-     produc-
tion (  Fig. 6 D  ). These data support the concept that TNFR25 
signals play a critical role in pulmonary immune responses and 
lung infl  ammation by triggering IL-13 production by NKT 
    Figure 7.         TNFR25 signals on NKT cells are required for induction 
of lung infl  ammation.   NKT-defi  cient J    18 KO mice (  28  ) were primed 
with ovalbumin and alum as in our standard protocol in Materials and 
methods. On day 11, the mice received 3.1 million purifi  ed NK/NKT cells 
containing 1 million WT NKT cells or DN TNFR25-tg NKT cells (DN NKT) or 
PBS by i.v. adoptive transfer, as indicated. The mice were exposed to oval-
bumin aerosol on day 12 and analyzed on day 15. WT mice and J   18  KO 
mice receiving WT NKT cells by adoptive transfer served as positive con-
trols for induction of lung infl  ammation. J    18 KO mice, immunized and 
ovalbumin aerosolized without adoptive cell transfer, served as negative 
controls. The data of three independent experiments and two mice in 
each group are shown. (A) Eosinophils in BALF. Error bars represent the 
mean   ±   the SEM. (B and C) Cytokine and TL1A mRNA expression in bron-
chial lymph nodes (LN; B) and lung parenchyma (C) determined by real 
time Taqman PCR. The fold increase or decrease of mRNA in J   18  KO 
mice (J    ) adoptively transferred with WT NKT cells over mice adoptively 
transferred with DN TNFR25-tg NKT (DN NKT) cells is plotted.     JEM VOL. 205, May 12, 2008 
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  We were able to further support the role of TNFR25 on 
NKT cells through adoptive transfer experiments of NKT 
cells into NKT-defi  cient mice. NKT-defi  cient mice are re-
sistant to lung infl  ammation, but can be rendered susceptible 
by adoptive transfer of WT NKT cells before airway antigen 
exposure. On the other hand, adoptive transfer of IL-13  –  de-
fi  cient NKT cells is unable to restore lung infl  ammation in 
NKT-defi  cient mice (  23  ); similarly, we show that adoptive 
transfer of DN TNFR25-tg NKT cells is unable to restore 
lung infl  ammation. This fi  nding is consistent with the inter-
pretation that TNFR25 signals in vivo are required to trig-
ger IL-13 secretion by NKT cells in the ovalbumin model of 
lung infl   ammation. Absence of either IL-13 or TNFR25 
signals triggering IL-13 release by NKT cells results in 
aborted lung infl  ammation upon airway antigen exposure of 
primed mice. 
  TNFR25 is triggered by ligation to TL1A, as indicated by 
the antibody blockade using antagonistic anti-TL1A. TL1A is 
not detectable by PCR in the normal lung, but is up-regulated 
on the mRNA level as measured by Taqman assays in bron-
chial lymph nodes and lung tissue during lung infl  ammation. 
CD4 and CD8 T cells and APC can express TL1A upon acti-
vation. It is known that TL1A can be released as soluble ligand 
after proteolytic cleavage. Therefore, it is possible that TL1A 
may act as soluble mediator or as cell-bound ligand to trigger 
TNFR25 on NKT and T cells. 
  Regardless of the specifi  c details of TL1A expression as 
soluble or cell-bound molecule, our data add an important 
molecular component (TNFR25/TL1A) to our understand-
ing of the pathogenesis of lung infl  ammation, a cardinal feature 
of asthma. Our data support and extend previous fi  ndings of 
the importance of NKT cells and IL-13 in lung infl  ammation 
and in airway hyperreactivity. We present evidence that 
TNFR25 is the essential trigger for IL-13 release by NKT cells 
and for amplifi  cation of the Th2 response by Th2-polarized 
CD4 cells. These functions distinguish TNFR25 from Ox40, 
which supports survival of Th2-polarized CD4 T cell (  36, 37  ). 
In contrast, TNFR25 specifi  cally promotes the exertion of ef-
fector function of Th2-polarized cells, in addition to triggering 
IL-13 production by NKT cells. Whether Ox40 has any ef-
fects on NKT cells is not known. 
  Attenuation of lung infl  ammation is an important goal for 
the treatment of atopic asthma, which is inexorably rising in in-
cidence and severity. Our data show that lung infl  ammation can 
be inhibited by TNFR25 blockers in mice that have already 
been primed and sensitized. Importantly, TL1A blockade even 
72 h after airway antigen reexposure of sensitized mice, for 4 h 
before analysis, attenuates lung infl  ammation. This fi  nding, and 
the observation that TNFR25 appears to be very far upstream in 
the infl  ammatory sequence, may make it a valuable target for 
drug development for the treatment of asthma patients. 
    MATERIALS AND METHODS   
  Media and reagents.     Cells were cultured in Iscove  ’  s Modifi  ed Dulbec-
co  ’  s Minimal Essential Medium (Invitrogen) supplemented with 10% 
heat-inactivated FBS (Invitrogen), 10   μ  g/ml gentamycin (Invitrogen), and 
trigger for IL-13 secretion by NKT cells and Th2 cytokine 
production in the lung is TNFR25. This conclusion is sup-
ported by the evidence that TNFR25 in vitro acts as a co-
stimulus for IL-13 secretion by NKT, together with the 
activation of the invariant TCR by glycosphingolipid or low 
concentration of anti-CD3. TNFR25 signals also increase 
the number of IL-13  –  producing NKT cells, by inducing 
IL-13  –  producing cells at intermediate TCR stimulation. The 
eff  ect of TNFR25 co-stimulation on NKT cells appears to be 
specifi  c for IL-13, and to a lesser extent IL-4, whereas IFN-     
secretion by NKT cells is not co-stimulated by TNFR25. 
  The importance of TNFR25 signals in lung infl  amma-
tion is further supported by in vivo blocking experiments us-
ing an antagonistic anti-TL1A antibody and by genetic 
blockade of TNFR25 signals with a DN mutant TNFR25 
transgene. In vivo, blockade of TNFR25 results in inhibition 
of all signs of lung infl  ammation, including down-regulation 
of IL-4, -5, and -13 mRNA in lung parenchyma and bron-
chial lymph nodes, diminished Th2 cytokine production af-
ter ex vivo antigen restimulation of draining bronchial lymph 
nodes, diminished BALF eosinophilia, and diminished mucus 
production. The potent eff  ect of anti-TL1A on BALF eosin-
ophilia is noteworthy. 4 h of TL1A blockade, from 72 to 76 
h after airway antigen exposure, was reproducibly able to sig-
nifi  cantly reduce BALF eosinophilia by     50%. It is known 
that eosinophil-accumulation peaks on day 3 after airway an-
tigen exposure. In culture, eosinophils are short lived unless 
IL-5 is added, which supports eosinophil survival (  31  –  33  ). 
Thus, TL1A may be needed for stimulation of TNFR25 sig-
nals for continued IL-5 and -13 production, thereby sustain-
ing continued survival and/or migration of eosinophils into 
BALF. In support of this hypothesis, we found that in vitro 
continuous anti-CD3 stimulation of CD4 cells maintains 
high levels of TL1A expression for   >  4 d. Withdrawal of 
TCR stimulation results in TL1A down-regulation within 
24 h (unpublished data). Alternatively, eosinophils may ex-
press TNFR25, which has not been studied so far, and it may 
act as a direct survival factor. Finally, it has been reported that 
TL1A is expressed by certain endothelial cells (  11  ), and thus 
may be involved in eosinophil migration and extravasation. 
  The data also indicate that TNFR25 co-stimulation dur-
ing secondary activation of CD4 cells greatly amplifi  es Th2 
cytokine production. According to recent reports, Th2 po-
larization involves gain of Th2 eff  ector function, followed by 
ITK-mediated signals that are required for the exertion (am-
plifi  cation) of Th2 eff  ector function upon TCR restimula-
tion (  34, 35  ). The upstream signals leading to ITK activation 
have not been identifi  ed. It is possible that TNFR25 signals 
play a role in this sequence; a hypothesis is currently under 
investigation. In support, we have found that functional 
TNFR25 transgenes on T cells result in spontaneous Th2 
production of CD4 cells upon primary activation (unpub-
lished data). The strong eff  ects of TNFR25 blockade on lung 
infl  ammation, therefore, appear to be caused by the dual ac-
tion of TNFR25, fi  rst at the level of NKT cells and second at 
the level of polarized CD4 T cells. 1046 TNFRSF25 IN ASTHMA | Fang et al.
facilities. The University of Miami Animal Care and Use Committee ap-
proved all animal use procedures. 
  T cell proliferation assay.     Splenocytes were plated in triplicate at 1   ×   10  5   
cells/well in 96-well fl  at-bottom plates. Cells were activated with 2   μ  g/ml 
immobilized anti-CD3 with or without 1   μ  g/ml soluble anti-CD28, or with 
5   μ  g/ml ConA or 10 ng/ml PMA and 400 ng/ml ionomycin. For T cell pro-
liferation, purifi  ed CD4 T cells at 1   ×   10  5   cells/well or CD8 T cells at 5   ×   10  4   
cells/well were stimulated with 2   μ  g/ml coated anti-CD3 and 1   μ  g/ml solu-
ble anti-CD28. Recombinant mIL-2 was added to the culture at 1,000 U/ml 
in the indicated experiments. Cells were cultured for 72 h and pulsed for the 
last 6 h of incubation, with 1   μ  Ci/well of [  3  H]thymidine (PerkinElmer), and 
thymidine incorporation was quantitated using a scintillation counter. 
  Murine CD4 or CD8 T cells were purifi  ed from splenocytes and/or 
lymph nodes by negative selection using the SpinSep kit (StemCell Tech-
nology Inc.) according to the manufacturer  ’  s protocol. The purity was rou-
tinely     90  –  96%, as examined by FACS analysis. 
  Immunization protocol for the murine model of allergic asthma.   
  DN TNFR25-tg mice generated as described above and backcrossed at least 
seven generations into the C57BL/6J background were compared with WT 
C57BL/6J mice purchased from the National Cancer Institute. Mice were 
sensitized by i.p. injection of 66   μ  g ovalbumin (crystallized chicken egg al-
bumin, grade V; Sigma-Aldrich) absorbed to 6.6 mg aluminum potassium 
sulfate (alum; Sigma-Aldrich) in 200   μ  l PBS on day 0. On day 5, mice were 
boosted intraperitoneally with the same dose of ovalbumin in alum. On day 
12, mice were aerosol challenged with 0.5% ovalbumin in PBS for 1 h using 
an Ultrasonic Nebulizer (MABIS Healthcare, Inc.). Mice were assessed for 
allergic infl  ammation of the lungs 1  –  3 d (on day 13 to 15) after the aerosol 
exposure. Mice were killed by inhalation of CO  2.   After cannulation of the 
trachea, the lung was lavaged 4 times with 1 ml of PBS. Cells recovered from 
the BAL fl  uid were counted and used for cytospin preparations (  ≤  50,000 
cells/slide). More than 200 cells were counted for each cytospin slide stained 
with Wright-Giemsa stain (Sigma-Aldrich) to determine diff  erential  cell 
counts for macrophages, eosinophils, lymphocytes, and neutrophils. 
  Lung histology.     Lungs were removed from mice after the bronchial lavage 
procedure and fi  xed in 10% neutral buff  ered formalin. Samples were submit-
ted to the Histopathology Core of the Sylvester Cancer Center at the Uni-
versity of Miami Miller School of Medicine, where specimens were 
embedded, sectioned, and stained with HE. Sections were also stained with 
PAS to determine mucus production. Five lung sections of each experimen-
tal animal were evaluated. Slides were coded and scored in a blinded fashion. 
The following scoring system was used for HE-stained sections (  39  ). A value 
from 0 to 3 per criterium was adjudged to each tissue section scored. Two 
criteria were scored to document the pulmonary infl  ammation: peribron-
chial infl  ammation and perivascular infl  ammation. A value of 0 was adjudged 
when no infl  ammation was detectable, a value of 1 for occasional cuffi   ng 
with infl  ammatory cells, a value of 2 when most bronchi or vessels were sur-
rounded by a thin layer (1  –  5 cells) of infl  ammatory cells, and a value of 
3 when most bronchi or vessels were surrounded by a thick layer (  >  5 cells) 
of infl  ammatory cells. For PAS-stained sections, the scoring system accord-
ing to Roh et al. (  40  ) was used. Section analysis for PAS staining was also 
performed in a blinded fashion using a quantitative scoring system (0  –  4), 
where 0 represented no epithelial staining, 1 represented slight epithelial 
staining, 2 represented moderate epithelial staining, 3 represented heavy epi-
thelial staining, and 4 represented massive epithelial staining. 
  ELISA for serum total IgE and ovalbumin-specifi  c IgE.     Mice were bled 
before sensitization (day 0), 3 d after aerosol challenge (day 15), and, in some ex-
periments, 1 d before aerosol challenge (day 11). The total IgE level was quanti-
tated by ELISA according to the manufacturer  ’  s protocol (BD Biosciences). 
Ovalbumin-specifi  c IgE was determined in Sandwich ELISA by fi  rst coating the 
plate with 0.01% ovalbumin in PBS, followed by loading diluted serum samples 
and the secondary biotin  –  labeled anti-IgE antibody (BD Biosciences). 
50   μ  M     -mercaptoethanol (Bio-Rad Laboratories). Monoclonal anti  –  mouse 
and anti  –  human CD3 were purifi  ed from cultured supernatants of the 2C11 
(American Type Culture Collection). Monoclonal anti  –  mouse CD28 was 
purchased from eBioscience. ConA, PHA, and LPS were purchased from 
Sigma-Aldrich. Recombinant murine IL-2 and -15 was obtained from Bio-
Source International). PMA, ionomycin, H7, and cycloheximide were pur-
chased from Calbiochem. 
  Directly conjugated monoclonal antibodies, including FITC-CD4, Cy-
chrome-CD4, PE-CD8    , Cychrome-CD8    , FITC-B220, PE-B220, 
FITC-CD25, PE-CD11c, PE-DX5, FITC-CD3, PE-NK1.1, PE-Annexin 
V, and 7-amino actinomycin were purchased from BD Biosciences. Hamster 
IgG control was purchased from eBioscience. 
  Generation of monoclonal antibodies against mTNFR25 and 
mTL1A.     Armenian hamsters were immunized intraperitoneally 3 times bi-
weekly with 50   μ  g of mTNFR25-Ig or mTL1A-MBP (maltose binding 
protein) in Freund  ’  s adjuvant. 3 d before the fusion, hamsters were boosted 
with 50   μ  g of the respective proteins i.v. Hamster splenocytes were fused 
with the murine myeloma SP20 with PEG, and then plated in methylcellu-
lose-based medium for 2 wk using ClonaCell-HY kit (StemCell Technol-
ogies). 1,000 colonies were picked and analyzed by ELISA in plates coated 
with the immunizing fusion protein or control protein-Ig fusion protein. 
Supernatants from positive clones were tested for the ability to detect 
TNFR25 or TL1A in transfected cells by fl  ow cytometry and Western blot-
ting. Antibodies were purifi  ed from a Nutridoma-SP (Roche) supernatant 
on a protein G column, dialyzed into PBS, and fi  lter sterilized. 
  Flow cytometric analysis for the expression of TNFR25 and TL1A.   
  Single-cell suspensions were prepared from lymphoid organs indicated in the 
individual experiment. Before staining, cells were treated with purifi  ed anti  –
  mouse CD16/CD32 (Fc-    III/II receptor; BD) and purifi  ed human IgG 
(Jackson ImmunoResearch Laboratories) to block nonspecifi  c binding to 
FcRs. Cells were stained with Armenian hamster anti  –  mouse TNFR25 or 
anti  –  mouse TL1A for 30 min at 4  °  C. Cells were washed in FACS buff  er 
(PBS containing 0.5% BSA and 2 mM EDTA) and stained with biotin-
labeled goat anti  –  Armenian hamster IgG (Jackson ImmunoResearch Labora-
tories) for 30 min at 4 °  C. Cells were washed and stained with Streptavidin-PE 
or Streptavidin-Cychrome (BD Biosciences) for 30 min at 4  °  C. Cells were 
washed and stained with directly conjugated cell surface markers for distinct 
cell populations. Samples were analyzed using a FACS LSR instrument (Bec-
ton Dickinson) and CellQuest software. 
  Nuclear extract preparation and electrophoretic mobility shift as-
says for NF-    B activation.     10  7   EL4-TNFR25 cells were treated with 
soluble or membrane-bound TL1A or with the TNFR25 agonistic antibody 
4C12, as indicated in the fi  gure legends, and then collected by centrifugation 
at 800   g   for 5 min. Nuclear extracts were isolated using a minipreparation 
protocol and subjected to EMSA as previously described (  38  ). Nuclear 
extracts (6   μ  g) were incubated at room temperature for 20 min with a   32  P-
labeled high-affi   nity      B probe, followed by resolving the DNA  –  protein 
complexes on native 5% polyacrylamide gels. 
  Generation of transgenic mice.     A murine DN mutant of TNFR25 lack-
ing the intracellular domain (DN TNFR25, aa 1  –  234) was cloned under the 
human CD2 promoter and local control region (gift from A. Singer, Na-
tional Institutes of Health) using the restriction endonuclease sites EcoRI 
and SalI. Microinjections of DNA into the fertilized eggs were performed by 
the transgenic facility at the University of Miami Miller School of Medicine. 
Potential founders were screened by PCR of DNA from tail biopsies. The 
primer pair was located upstream and downstream of the cloning sites. 
The upstream primer is 5    -CGCTCTTGCTCTCTGTGTATG-3     and the 
downstream primer is 5    -CTGCCAGCCCTCTTCCATC-3    . Transgenic 
mice were bred into the C57BL/6J background by serially mating hemizy-
gous transgenic animals with WT C57BL/6J (The Jackson Laboratory). 
All mice were used at 6  –  12 wk of age and were maintained in pathogen-free JEM VOL. 205, May 12, 2008 
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5   μ  g/ml agonistic anti-TNFR25 antibody 4C12. After 48 h, supernatants 
were harvested and analyzed by ELISA for IL-13, IL-4, and IFN-    . 
  For intracellular cytokine staining, enriched NK/NKT cells were cul-
tured at 2   ×   10  5   cells/well in a 96-well, fl  at-bottom plates for 72 h in the 
presence of plate-bound anti-CD3, as indicated in the fi  gures with or with-
out anti-TNFR25 at 5   μ  g/ml. Activated cells were harvested after 67 h, 
washed twice in media, and counted. Cells were replated at 2   ×   10  5   cells per 
well in 96 fl  at-bottom well plates for 5 h in the presence of PMA (at 10 nM) 
and ionomycin (at 0.25   μ  M) and Monensin (at 2   μ  M). After the 5 h, cells 
were harvested (not counted) and transferred directly into staining tubes (3  –
  4 wells worth of cells per tube = 8   ×   10  5   cells). Staining began with cell sur-
face stain with CD3 PerCP and NK1.1 FITC. Cells were then fi  xed and 
permeabilized at room temperature, followed by an incubation with the 
specifi  c intracellular cytokine stain (IL-13 Alexa Fluor 647 and IFN-     Pa-
cifi  c Blue) or isotype control. For the IL-13 staining control, 1   μ  g rIL-13 was 
used to preblock anti  –  IL-13, which then proceeded to stain as with the un-
blocked IL-13 antibody. All antibodies and reagents used for the intracellular 
cytokine stain were purchased from eBioscience, except for the CD3 PerCP 
which was purchased from BD Biosciences. Data were acquired on BD LS-
RII with BD DIVA software. Files were then converted and analyzed using 
Cell Quest. 
  Statistical analyses.     Statistical analyses using a two-tailed Student  ’  s   t   test 
were performed with GraphPad Prism Software. P   <   0.05 is considered sig-
nifi  cant. Data in the text are presented as the mean   ±   the SEM. 
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  In vitro restimulation of bronchial lymph node cells and cytokine 
production.     3 d after aerosol challenge, bronchial lymph nodes were har-
vested, and single-cell suspensions were prepared. Cells were seeded into 
round-bottom 96-well plates at 1   ×   10  6   cells/well and cultured with 100   μ  g/ml 
ovalbumin for 4 d. Supernatants were collected for cytokine ELISA assays 
as described. 
  Cytokine mRNA levels were measured by quantitative Taqman PCR. 
Before the homogenizing procedure, lungs and lymph nodes were suspended 
in 3 and 1.5 ml, respectively, of ice cold lysing buff  er RLT (RNeasy mini 
kit; QIAGEN). Homogenization was performed in a 50-ml conical centri-
fuge tube, using a 12-mm generator attached to a standalone Polytron PCU-
2 (Brinkman) homogenizer unit. Tubes were maintained on ice throughout 
the homogenization process. Subsequently, 0.7 ml of homogenized tissues 
was further homogenized using QIAshredder Mini Spin columns (QIA-
GEN). Extraction of RNA was performed using the RNeasy mini kit fol-
lowing the manufacturer  ’  s recommendations for purifi  cation of total RNA 
from animal tissue. An on-column DNase digestion was also performed us-
ing RNase-Free DNase (QIAGEN). The quality of RNA was assessed by 
capillary chromatography and quantitated by spectrophotometry. Reverse 
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tect reverse transcription kit (QIAGEN), following recommendations from 
the manufacturer. Real-Time PCR was performed in a 7300 Real-Time 
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A(Mm00770031_m1) were performed and normalized to GAPDH (part 
number 4352932E; Applied Biosystems) gene expression, and fold diff  er-
ences calculated using the     Ct method. 
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  Preparation of NKT cells for in vitro evaluation and adoptive transfer.   
  J    18 KO mice (  27  ) were a gift from M. Lotze (University of Pittsburgh, 
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